Rising Alarms Over Substandard Drugs

NITI Aayog has initiated a review following alarming data from the Central Drugs Standard Control Organisation (CDSCO), which revealed that multiple micro, small, and medium enterprise (MSME) pharmaceutical firms in India are producing substandard medications, prompting calls for strengthened oversight and urgent quality control measures.

Ministry Proposes License Revocation for Failing Companies

In response, the Ministry of Health is considering stiff penalties, including revoking manufacturing licenses for firms whose products consistently fail quality tests, underscoring a government-level push to enhance accountability and ensure only safe and effective medicines reach the market

Alignment with Global Standards & Regulatory Reforms

Aligning with previous NITI Aayog recommendations, regulatory frameworks are being updated to meet International Council for Harmonisation (ICH) and WHO standards, including revised Schedule M rules to enforce Good Manufacturing Practices (GMP)

Proposed National Task Force Against Counterfeit Drugs

The Aayog is also reviewing proposals to form a specialized task force—comprising senior IPS officers and trained drug inspectors—to combat the rising threat of counterfeit medications. Regulators have reported a troubling 50% surge in fake drugs, making enhanced enforcement and digital traceability (such as secure QR codes) top priorities

Implications and Next Steps

1. Stricter Enforcement
   • Implementation of license revocation and more frequent inspections for non-compliant manufacturers.
2. Regulatory Alignment
   • Fast-tracking regulatory amendments to harmonize with global drug safety frameworks and ensure consistent drug quality.
3. Task Force Establishment
   • Establishing a dedicated enforcement task force to crackdown on counterfeit drugs and introduce QR code-based verification systems.
4. Public Health Assurance
   • These measures aim to restore confidence in India’s pharmaceutical supply chain, safeguarding both domestic patients and international markets relying on Indian generics.

In summary, NITI Aayog’s review process marks a decisive shift to reinforce pharmaceutical quality in India. By enforcing stricter regulatory frameworks, punishing non-compliance, and deploying enhanced anti-counterfeit mechanisms, these initiatives seek to uphold patient safety and solidify India’s reputation as a global hub for high-quality, affordable medicines.